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LETTERS TO THE EDITOR
EGFR Mutant Lung
Adenocarcinomas in
Patients with Germline
BRCA Mutations
To the Editor:
We have been treating a 47-year-old
man of European descent who was diag-
nosed with metastatic lung adenocarci-
noma at the age of 43. The patient is a
“never smoker” (i.e., a person who
smoked less than 100 cigarettes in a life-
time) whose tumor was found to harbor
a somatic mutation in epidermal growth
factor receptor (EGFR) gene (H773-
V774HVdup in exon 20). His family his-
tory is significant for breast cancer in ma-
ternal relatives and lung cancer in his
maternal grandfather who also never
smoked. The pedigree for this patient is
depicted in Figure 1. The patient was also
found to have a germline mutation in
breast cancer 2 (BRCA2) in exon 25
(c.9641insT). This frameshift mutation
leads to premature truncation of the pro-
tein at amino acid 3149.
We subsequently identified a man
of European descent with a minimal
smoking history who was diagnosed with
an EGFR mutant (exon 19 deletion) stage
IIIB lung adenocarcinoma at the age of 74.
The patient’s daughter, mother, and ma-
ternal aunt all had breast or ovarian can-
cers. DNA from the patient and daughter
harbored the same BRCA2 8867del5
mutation, which leads to premature
truncation of the BRCA2 protein at
amino acid 2904.
Mutations in the kinase domain of
EGFR are more commonly found in lung
adenocarcinomas from never smokers,
East Asian populations, and in tumors of
adenocarcinoma histology.1 Why certain
patients are susceptible to the develop-
ment of EGFR mutant tumors is currently
unknown. Given the nature of EGFR ki-
nase domain mutations (especially in-
frame multinucleotide deletions and dupli-
cations), we hypothesized that genetic
susceptibility to DNA repair defects could
predispose certain individuals to the de-
velopment of EGFR mutant tumors. Con-
sistent with this notion, mice carrying in
the Brca1 locus a hypomorphic modifica-
tion (Brca1tr) that eliminates the C-termi-
nal half of the protein product develop
bronchioloalveolar lung tumors.2
On Institutional Review Board-
approved protocols, we screened 110
Jewish patients with lung cancer and
found that three harbored germline BRCA
mutations (2.7%). This rate is similar to
the 2.5% expected in the general Ash-
kenazi population. None of their lung tu-
mors harbored EGFR mutations. Con-
versely, we screened 13 patients of
Ashkenazi Jewish descent whose lung tu-
mors harbored EGFR mutations and
found that none had germline BRCA1/2
mutations. Thus, we did not find a clear
epidemiologic association between EGFR
mutant lung cancers and BRCA mutation
carriers. In the future, larger association
studies and further molecular analysis of
individual cases like these could provide a
clue to the etiology of EGFR mutations in
lung cancer.
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FIGURE 1. The family pedigree for the index case, indicated by arrowhead. One
quarter shade (square or circle) denotes one cancer diagnosis, and a half shade
denotes two cancer diagnoses.
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